Virax Biolabs Group (VRAX) Financial Ratios

For fiscal 2026 (fiscal year ended Mar 31, 2026), Virax Biolabs Group had return on equity of -78.6% (up from -114.5%), debt-to-equity of 0.06 (down from 0.07), a current ratio of 9.97 (up from 7.27) and return on assets of -54.2% (up from -63.8%). A current ratio of 9.97 means current assets exceed current liabilities.

Virax Biolabs Group Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Income Statement Balance Sheet Cash Flow Ratios

Scroll to see more

Breakdown	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period ending	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Valuation Ratios
P/S Ratio	131.40	781.84	10.83	1262.87	-	-
P/B Ratio	0.22	0.91	0.33	1.21	-	-
Price/Tangible Book	0.21	0.88	0.32	1.21	-	-
Enterprise Value Ratios
EV/Revenue	-	-	-	701.38	-	-
Profitability & Returns
Return on Equity (ROE)	-78.65%	-114.47%	-95.98%	-141.63%	-	65.75%
Return on Assets (ROA)	-54.23%	-63.77%	-50.14%	-72.67%	-2453.52%	-2071.47%
Return on Invested Capital (ROIC)	-	-	-	-	-	61.99%
Return on Capital Employed (ROCE)	-83.80%	-105.60%	-115.40%	-64.40%	144.90%	62.98%
Leverage & Solvency Ratios
Debt/Equity	0.06	0.07	0.04	0.02	-	0.00
Liquidity Ratios
Current Ratio	9.97	7.27	25.94	10.61	0.04	0.05
Quick Ratio	9.55	6.47	23.00	10.35	0.02	0.02
Efficiency Ratios
Asset Turnover	0.00	0.00	0.02	0.00	-	3.98
Inventory Turnover	0.04	0.32	1.01	0.44	-	12.65
Yield & Distribution Ratios
Earnings Yield	-307.75%	-122.45%	-397.61%	-50.48%	-	-
FCF Yield	-298.80%	-104.40%	-433.98%	-38.66%	-	-
Buyback Yield	-166.46%	-85.92%	-88.76%	-11.15%	-	-154.71%
Total Return	-	-	-	-	-	-154.71%

Source: Company financial statements from annual and quarterly filings. Data as of Mar 31, 2026. Data sources and methodology

Frequently Asked Questions About Virax Biolabs Group Financial Ratios

What is Virax Biolabs Group's return on equity?

Virax Biolabs Group's return on equity (ROE) was -78.6% for fiscal 2026 (period ended Mar 31, 2026). It was -114.5% a year earlier.

What is Virax Biolabs Group's debt-to-equity ratio?

Virax Biolabs Group's debt-to-equity ratio was 0.06 for fiscal 2026 (period ended Mar 31, 2026). It was 0.07 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition